What’s Going On With WD-40 Stock After Hours?

WD-40 Co (NASDAQ: WDFC) shares are moving slightly lower in Thursday's after-hours session after the company reported fiscal second-quarter financial results.

WD-40 Co (NASDAQ:WDFC) shares are moving slightly lower in Thursday’s after-hours session after the company reported fiscal second-quarter financial results.

  • Q2 Revenue: $130.19 million beat estimates of $125.85 million
  • Q2 EPS: $1.21 beat estimates of $1.01

“While sales volumes in the second quarter were lighter than we anticipated, we continue to believe that most of our growth this fiscal year will be weighted toward the second half of the year,” said Steve Brass, president and CEO of  WD-40.

“Although gross margin in the second quarter improved compared to the same period last year, there continues to be pressure on gross margin. Progress is seldom linear, and many factors are currently impacting gross margin.”

WD-40 expects full-year 2023 revenue of $535 million to $560 million. The company expects full-year earnings to be in a range of $4.80 to $5 per share.

It appears the stock is reacting negatively to the cautious commentary on gross margins. It’s also possible that the stock is facing some selling pressure related to weak earnings guidance. At least one analyst was expecting full-year earnings of approximately $5.24 per share. 

From Last Week: Favorable Spot Prices For Oil Will Benefit WD-40 In Q2, Says Analyst

WDFC Price Action: WD-40 has a 52-week high of $209.33 and a 52-week low of $145.51.

The stock was down 4.65% at $170.30 at time of publication. 

Photo: Tim Reckmann from Flickr.

Total
0
Shares
Related Posts
Read More

BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).   NE3107 is

BIVI

Read More

Sosei Heptares and AbbVie Announced New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases; Sosei Heptares Eligible to Receive up to $80M in Upfront, Near-term Milestone Payments; Up to $1….

Sosei Group Corporation ("the Company"; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR)

ABBV